Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2005

View Archived Issues

CL-316243/oleoyl-estrone shows promise for obesity

TLR2 antagonists emerge from Eisai R&D

Recent patents describe novel antiinfective agents

Patents report therapeutic agents for thrombotic disorders

LK-732: A direct thrombin inhibitor effective in preclinical models of venous thrombosis

510(k) clearance for DynaGraft II in dental applications

Novel alpha7 nicotinic receptor agonist demonstrates efficacy for inflammatory pain

Cotreatment with DA-9601 and omeprazole produces synergistic antiulcer effects in animal models

Safety of anti-HIV PRO-2000 vaginal gel shown in healthy women

Antiviral efficacy of aplaviroc against a broad array of HIV-1 envelopes from infected subjects

Betaine displays anticoagulant activity in healthy individuals

Novel Cdk5 inhibitor shows selectivity and inhibits tau phosphorylation

ITI-367: A novel inhibitor of HIV-1 nuclear translocation

CaMKII represents a novel target to halt the progression from acute to chronic pain

Antiviral efficacy and safety of Reverset shown in the phase IIb Reverset Study 203

Power3 Medical submits pre-IDE for NuroPro tests for ALS

Neurochem begins rolling NDA submission for Fibrillex

Agreement on design of phase III study for Viprinex

MLN-1202 begins new phase II study for atherosclerotic cardiovascular disease

Orphan drug status for AP-23573 for soft-tissue and bone sarcomas

Novel fusion protein for the inhibition of nNOS with promising results in pain models

Local administration of ENT-103 elicits prolonged antinociception

Leuplin approved for premenopausal breast cancer in Japan

Taxotere approved for endometrial cancer in Japan

Humira receives new European approvals

Anidulafungin NDA filing for invasive candidiasis/candidemia

Oral solution formulation of Namenda now available

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...